United StatesBreaking News

Seres Therapeutics (NASDAQ:MCRB) announced a series of strategic financial moves aimed at strengthening its liquidity position.

Climb Bio (NASDAQ:CLYM) announced initial Phase 1 safety and pharmacokinetic data for its lead product candidate, CLYM116, at the 2026 European Renal Association (ERA) Congress in Glasgow.

G-III Apparel Group (NASDAQ:GIII), the owner and licensee of a diverse portfolio of fashion brands, reported its financial results for the first quarter of fiscal 2027, highlighting the impact of a significant regulatory refund alongside its strategic pivot toward new brand ownership.

S&P Dow Jones Indices will not shorten its existing eligibility requirements for benchmarks including the S&P 500, closing the door to fast entry for big tech IPOs like SpaceX. Mandeep Singh of Bloomberg Intelligence has more.

ABM Industries (NYSE:ABM), a prominent provider of integrated facility, engineering, and infrastructure solutions, posted record revenue for its fiscal second quarter of 2026, as the company benefited from significant expansion across its core business segments.

Scott Wiener, Senator at California State Senate discusses AI regulation, transparency and public policy frameworks with Bloomberg's Brad Stone at Bloomberg Tech 2026 in San Francisco.

The Board of Directors of Trane Technologies (NYSE:TT), a global leader in climate innovation, has declared a quarterly dividend of $1.05 per ordinary share.

Ali Ghodsi, Co-Founder & CEO at Databricks discusses unified data platforms, AI infrastructure and enterprise strategy with Bloomberg's Tom Giles at Bloomberg Tech 2026 in San Francisco.

Adam Katz, Head of Entrepreneurs & Founders at Corient speaks with Bloomberg's Mark Miller about founder strategy and wealth management trends at Bloomberg Tech 2026 in San Francisco.

Elizabeth Hackenson, Chief Information Officer at Schneider Electric speaks with Bloomberg's Sofia Economopoulos about sustainability and digital infrastructure at Bloomberg Tech 2026 in San Francisco.

Underwriters on SpaceX's $75 billion initial public offering have been told not to accept orders from investors in Hong Kong and China, due to regulatory and compliance risks related to US restrictions around the export of critical technology. Benedikt Kammel reports on Bloomberg Television.

Gilead Sciences (NASDAQ:GILD) and Lakefront Biotherapeutics (NASDAQ:LKFT) have finalized the acquisition of Ouro Medicines, a strategic move designed to bolster their respective inflammation and immunology portfolios with next-generation T cell engager therapies.